A1 Refereed original research article in a scientific journal
Prognostic potential of circulatory miR-19a-3p, miR-19b-3p, and miR-329–3p for future hypertension diagnosis
Authors: Kostiniuk, Daria; Blankenstein, Antti; Rajić, Sonja; Ciantar, Joanna; Mononen, Nina; Lyytikäinen, Leo-Pekka; Seppälä, Ilkka; Mishra, Pashupati P.; Juonala, Markus; Waldenberger, Melanie; Elovainio, Marko; Oksala, Niku; Kähönen, Mika; Hutri, Nina; Raitakari, Olli; Kleber, Marcus E.; März, Winfried; Lehtimäki, Terho; Marttila, Saara; Raitoharju, Emma
Publisher: Lippincott
Publication year: 2026
Journal: Journal of Hypertension
Volume: 44
Issue: 5
First page : 811
Last page: 822
ISSN: 0263-6352
eISSN: 1473-5598
DOI: https://doi.org/10.1097/HJH.0000000000004272
Publication's open availability at the time of reporting: Open Access
Publication channel's open availability : Partially Open Access publication channel
Web address : https://doi.org/10.1097/hjh.0000000000004272
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/516224146
Self-archived copy's licence: CC BY
Self-archived copy's version: Publisher`s PDF
MicroRNAs have been suggested as essential hypertension biomarkers, but evidence remains inconclusive due to limited high-throughput studies in population cohorts.
We analyzed data from the Young Finns Study (YFS) from 2011 and 2018–2020 to assess cross-sectional and prospective associations between circulatory microRNAs, blood pressure (BP), and hypertension. Hypertension risk prediction potential was assessed using nested logistic and Weibull survival models; model performance was evaluated with likelihood ratio (LR) test and c-statistic. All models were adjusted with relevant risk factors.
In 2011, whole blood microRNAs were profiled for 871 individuals (83 with hypertension); in 2018–2020, 760 were re-examined, with 67 newly diagnosed. Cross-sectionally, 16 miRNAs correlated with BP (Spearman, PFDR < 0.05); miR-122–5p (fold change = 1.33) and miR-144–5p (fold change = -1.10) differentiated hypertensive individuals (U test, PFDR < 0.05). Associations persisted in adjusted regression models and some replicated in LURIC (n = 999) and YFS serum data (n = 126). Prospectively, miR-19a-3p [odds ratio (OR) = 1.51, 95% confidence interval (95% CI): 1.14–2.18], miR-19b-3p (OR = 1.50, 95% CI:1.11–2.04), and miR-329–3p (OR = 0.58, 95% CI: 0.39–0.74) levels prognosed hypertension incident. miR-329–3p improved model fit (LR test, P = 2.85×10–4) and discrimination (c-statistic = 0.849, Δ = 0.026). miR-19b-3p predicted time to onset (hazard ratio = 2.13, 95% CI: 1.38–4.45), improving model fit (LR test, P = 0.0012) and time-dependent discrimination at 7 and 8-year horizons.
Our findings highlight both novel and previously reported miRNAs associating with BP and hypertension and suggest that miR-329–3p, miR-19a-3p, and miR-19b-3p as promising candidates for further investigation in hypertension risk prediction.
Downloadable publication This is an electronic reprint of the original article. |  |
Funding information in the publication:
D.K. was supported by funding from Aarne Koskelo Foundation, The Finnish Foundation for Cardiovascular Research, and the Tampere City Science Fund. PPM was supported by the Academy of Finland (Grant number: 349708). M.E. was supported by the Academy of Finland (Grant number: 339390)
The Young Finns Study has been financially supported by the Academy of Finland: grants 356405, 322098, 286284, 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117797 (Gendi), and 141071 (Skidi); the Social Insurance Institution of Finland; Competitive State Research Financing of the Expert Responsibility area of Kuopio, Tampere and Turku University Hospitals (grant X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation for Cardiovascular Research; Finnish Cultural Foundation; The Sigrid Juselius Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; Yrjö Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; Diabetes Research Foundation of Finnish Diabetes Association; EU Horizon 2020 (grant 755320 for TAXINOMISIS and grant 848146 for To Aition); European Research Council (grant 742927 for MULTIEPIGEN project); Tampere University Hospital Supporting Foundation, Finnish Society of Clinical Chemistry, the Cancer Foundation Finland, and BETTER4U_EU (Preventing obesity through Biologically and bEhaviorally Tailored inTERventions for you; project number: 101080117).
